May 2023/JCEM: This scientific statement expands the Society’s 2012 statement by focusing on endocrine disease disparities in the pediatric population and sexual and gender minority populations. Read the Statement.
June 2014/Endocrine Reviews: Despite the high prevalence of performance-enhancing drug (PED) use, media attention has focused almost entirely on PED use by elite athletes to illicitly gain a competitive advantage in sports, and not on the health risks of PEDs. Read the Statement.
April 2016/JCEM: Custom-compounded bioidentical hormone therapy (HT) has become widely used in current endocrine practice, which has led to unnecessary risks with treatment. Read the Statement.
September 2012/JCEM: Several themes emerged in the statement, including a need for basic science, population-based, translational and health services studies to explore underlying mechanisms contributing to endocrine health disparities. Read the Statement.
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.
